Medline Inc. - Class A common stock (MDLN)

35.65
+1.85 (5.47%)
NASDAQ· Last Trade: Jun 9th, 3:14 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close33.80
Open33.71
Bid35.61
Ask35.65
Day's Range33.65 - 35.65
52 Week Range32.81 - 50.88
Volume5,312,223
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume13,395,061

Chart

News & Press Releases

Securities Fraud Investigation Into Medline Industries, Inc. (MDLN) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) investors concerning the Company’s possible violations of the federal securities laws.
Medline Industries, Inc. (MDLN) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into Medline Industries, Inc. (MDLN) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Medline (NASDAQ:MDLN) Q1 Earnings: Revenue Beats, But Profits Slip on Tariff and Cost Pressureschartmill.com
Via Chartmill · May 6, 2026
Medline Inc. (NASDAQ:MDLN) Reports Q4 Revenue Beat but EPS Miss Amid Margin Pressurechartmill.com
Via Chartmill · February 25, 2026
Why Symbotic Stock Slumped 21% in May And Just Hit a 2026 Lowfool.com
Is something seriously wrong with the automation expert, or is this a market overreaction and an opportunity to buy?
Via The Motley Fool · June 8, 2026
Medline Inc. announces closing of upsized secondary offering of Class A common stock
NORTHFIELD, Ill., May 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · May 28, 2026
Medline announces participation in upcoming investor conferences
NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences.
By Medline Inc. · Via GlobeNewswire · May 27, 2026
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · May 21, 2026
Monashee Scales Back Its Bet on Structure Therapeuticsfool.com
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Via The Motley Fool · May 20, 2026
Medline Inc. announces launch of secondary offering of Class A common stock
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 60,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · May 20, 2026
Medline Reports First Quarter 2026 Results
NORTHFIELD, Ill., May 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care3, today reported its operating results for the three months ended March 28, 2026.
By Medline Inc. · Via GlobeNewswire · May 6, 2026
Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · March 10, 2026
Medline Inc. announces pricing of secondary offering of class A common stock
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock. The offering is expected to close on March 10, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · March 4, 2026
Medline Inc. announces launch of secondary offering of Class A common stock
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 75,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · March 3, 2026
Medline Reports Fourth Quarter and Full Year 2025 Results
NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care2, today reported its operating results for the three months and full year ended December 31, 2025.
By Medline Inc. · Via GlobeNewswire · February 25, 2026
Medline announces participation in the Barclays 28th Annual Global Healthcare Conference
NORTHFIELD, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, on Wednesday, March 11, 2026, at 9:30am ET.
By Medline Inc. · Via GlobeNewswire · February 18, 2026
Symbotic Could Be a Massive Breakout Stock in 2026 After a 150% Surge in 2025fool.com
Symbotic's big growth moves of 2025 should propel the company to new highs.
Via The Motley Fool · February 5, 2026
How the Largest IPO of 2025 Could Be Healthy for Your Portfoliofool.com
Medline is an appealing investment candidate – it has solid growth, operates in a steady industry, and a storied history.
Via The Motley Fool · February 5, 2026
Medline to report fourth quarter and full year 2025 results on February 25, 2026
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results.
By Medline Inc. · Via GlobeNewswire · January 28, 2026
A Fresh IPO That Long-Term Investors Shouldn’t Ignoremarketbeat.com
Via MarketBeat · January 14, 2026
Motley Fool Money: The Most Shocking Stories of 2025fool.com
Do you remember all of the surprises investors got in 2025? We had tariffs, AI upheaval, and even gold having a great year.
Via The Motley Fool · January 5, 2026
The 2025 IPO Market Review: A Year of Selective Recovery and the 2026 Outlook
As the final bell rings on 2025, the U.S. initial public offering (IPO) market has emerged from its multi-year hibernation, not with a frantic sprint, but with a calculated and selective stride. After the stagnation of 2023 and the tentative recovery of 2024, the past twelve months have seen
Via MarketMinute · December 31, 2025
Medline Announces Participation in J.P. Morgan 2026 Healthcare Conference
NORTHFIELD, Ill., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, January 13, 2026, at 3:00 pm Pacific Time.
By Medline Inc. · Via GlobeNewswire · December 30, 2025
Medline Industries (MDLN) Deep-Dive: The $54 Billion Return of a Healthcare Titan
The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity consortium—and decades of private family ownership before that—the medical supply titan has reclaimed its status as a public entity in the largest U.S. initial public [...]
Via PredictStreet · December 18, 2025